Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8456
Sealed predictions
- MAB21L3 in dopamine neurons, braak-0.07 (p 0.855) → -0.35 (p 0.361)receipt 8464
Swarm cases
receipt 8464: MAB21L3 in dopamine neurons, braak
- power
- full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.439, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAB21L3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts